{"analyses":[{"ciLowerLimit":"-1257.31","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"996.77","groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.5762","paramType":"Difference in LS Mean","paramValue":"-130.27","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-425.81","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1874.09","groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.1486","paramType":"Difference in LS Mean","paramValue":"724.14","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-997.94","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"1369.18","groupDescription":"MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.3972","paramType":"Difference in LS Mean","paramValue":"185.62","statisticalMethod":"MMRM analysis; 1-sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-785.82","upperLimit":"927.45","value":"70.81"},{"groupId":"OG001","lowerLimit":"-794.41","upperLimit":"675.49","value":"-59.46"},{"groupId":"OG002","lowerLimit":"39.43","upperLimit":"1550.48","value":"794.96"},{"groupId":"OG003","lowerLimit":"-561.29","upperLimit":"1074.16","value":"256.43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"13"}],"units":"Participants"}],"description":"Physical activity was monitored using accelerometry (wearable digital sensors). In this outcome measure mean activity level during maximum 6 minutes was considered. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using MMRM model.","dispersionType":"90% Confidence Interval","groups":[{"description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses).","id":"OG000","title":"Part A: Placebo"},{"description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG001","title":"Part A: Ponsegromab 100 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG002","title":"Part A: Ponsegromab 200 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG003","title":"Part A: Ponsegromab 400 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Censored analysis set:all evaluable participants.For participants who discontinued study intervention/received prohibited procedure/ prohibited medication,all observations post-discontinuation/post-procedure,were censored and treated as missing data.For participants who missed dose/received incomplete dose,all observations post-missed/incomplete dose were censored and treated as missing data.''Overall Number of Participants Analyzed'' =participants evaluable for this outcome measure at Week 12.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12","title":"Part A: Change From Baseline in Mean Activity Level During Maximum 6 Minutes at Week 12","type":"SECONDARY","unitOfMeasure":"Arbitrary units per day (au/day)"}